I think further htert sales (ie china), exosome revenue news, some sort of resolution to the court case would be good/great and failing that by the middle of 2022 an announcement about a partnership with a large US partner to run subb2m clincal trials will really bring this company out of speculative biotech status to a commercial reality as a cancer diagnostic with a world beating product. These are just some of the things they have laid out in previous announcements.
I think further htert sales (ie china), exosome revenue news,...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $65.06M | |||
| Open | High | Low | Value | Volume |
| 59.5¢ | 59.5¢ | 58.0¢ | $4.527K | 7.767K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38600 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 198 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |